ELSALYS BIOTECH is a specialty pharmaceutical company, part of the Mediolanum Farmaceutici Spa group, focused on innovative medicines to address haemato-oncology related life-threatening and rare diseases.
Following strategic acquisitions and targeted developments, ELSALYS is establishing an immunotherapeutic portfolio focused on niche specialty pharmaceuticals to answer unmet medical needs.
Today ELSALYS BIOTECH is conducting 3 proprietary development programs including Inolimomab (LEUKOTAC®), an immunotherapy antibody that has recently demonstrated its clinical superiority in Phase 3 in an orphan disease with very poor prognosis: steroid-resistant acute Graft-versus-Host Disease and that is currently benefitting of cohort ATU in France for the treatment of graft-versus-host disease, corticosteroid-resistant or corticosteroid-dependent, with grade II-IV.
Our commitment is to offer essential drugs meeting Public Health needs.
Founded in 2013, ELSALYS BIOTECH is located in the heart of the European cluster Lyon Biopole, in Lyon, France.